Aardvark Therapeutics

(NASDAQ) AARD

Current Price$3.71

Market Cap$85.96M

Since IPO (2025)-72%

5 YearN/A

1 Year-69%

1 Month-38%

Aardvark Therapeutics Financials at a Glance

Market Cap

$85.96M

Revenue (TTM)

$0.00

Net Income (TTM)

-$69.87M

EPS (TTM)

-$3.21

P/E Ratio

-1.23

Dividend

$0.00

Beta (Volatility)

1.70 (High)

Dividend

$0.00

Beta (Volatility)

1.70 (High)

Price

$3.71

Volume

139,871

Open

$3.91

Price

$3.71

Volume

139,871

Open

$3.91

Previous Close

$3.68

Daily Range

$3.66 - $3.98

52-Week Range

$3.35 - $17.94

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.70 (High)

Price

$3.71

Volume

139,871

Open

$3.91

Previous Close

$3.68

Daily Range

$3.66 - $3.98

52-Week Range

$3.35 - $17.94

Estimated Earnings Date

Aug 12, 2026

AARD News

Aardvark Therapeutics Reports Q2 Loss

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aardvark Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Tien Li Lee, MD

Website

www.aardvarktherapeutics.com

Headquarters

San Diego, CA 92122, US

AARD Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-59%

Return on Capital

-86%

Return on Assets

-71%

Earnings Yield

-81.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$85.96M

Shares Outstanding

21.82M

Volume

139.87K

Avg. Volume

226.44K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$62.73M

EBITDA

-$62.69M

Operating Cash Flow

-$54.17M

Capital Expenditure

-$95.00K

Free Cash Flow

-$54.27M

Cash & ST Invst.

$110.03M

Total Debt

$441.00K

Aardvark Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$85.96M

N/A

Market Cap/Employee

$3.91M

N/A

Employees

N/A

Net Income

-$21.59M

-131.9%

EBITDA

-$22.46M

-114.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$90.86M

-39.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$336.00K

-13.8%

Return on Assets

-70.87%

N/A

Return on Invested Capital

-85.90%

N/A

Free Cash Flow

-$18.87M

-65.7%

Operating Cash Flow

-$18.87M

-65.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PYXSPyxis Oncology, Inc.

PYXSPyxis Oncology, Inc.$1.78+4.09%

TNYATenaya Therapeutics, Inc.

TNYATenaya Therapeutics, Inc.$0.73-5.70%

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$13.10-3.75%

CRBUCaribou Biosciences, Inc.

CRBUCaribou Biosciences, Inc.$1.92-7.02%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$5.95-7.75%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$3.73-0.27%

ZURAZura Bio Limited

ZURAZura Bio Limited$3.40-7.36%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

MRVLMarvell Technology

MRVLMarvell Technology$263.47-0.17%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$11.87-0.11%

Questions About AARD

What is the current price of Aardvark Therapeutics?

Aardvark Therapeutics is trading at $3.68 per share.

What is the 52-week range for Aardvark Therapeutics?

Over the past 52 weeks, Aardvark Therapeutics has traded between $3.35 and $17.94.

How much debt does Aardvark Therapeutics have?

As of the most recent reporting period, Aardvark Therapeutics reported total debt of $336.00K.

How much cash does Aardvark Therapeutics have on hand?

Aardvark Therapeutics reported $62.44M in cash and cash equivalents in its most recent financial results.

What is Aardvark Therapeutics’s dividend yield?

Aardvark Therapeutics does not currently have a dividend yield.

Aardvark Therapeutics

Aardvark Therapeutics Financials at a Glance

AARD News

Aardvark Therapeutics Reports Q2 Loss

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aardvark Therapeutics

AARD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aardvark Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AARD

What is the current price of Aardvark Therapeutics?

What is the 52-week range for Aardvark Therapeutics?

How much debt does Aardvark Therapeutics have?

How much cash does Aardvark Therapeutics have on hand?

What is Aardvark Therapeutics’s dividend yield?

Premium Investing Services